Illumina's Q2 Rev Disappoints

Illumina Inc. (ILMN - Snapshot Report) said late Wednesday that second-quarter revenue will be lower than its own guidance, sending shares down by more than 11% today.

The company now expects to report sales of about $161 million, compared to its previous outlook of $168 million to $173 million.

Illumina cited lower foundation funding in a few key accounts, coupled with order delays linked to stimulus funding under the American Recovery & Reinvestment Act (ARRA), as reasons for the lower-than-expected performance.

The genetic analysis instrument producer also widened its full-year revenue outlook to between $690 million and $720 million, compared to the previous forecast of $700 million to $720 million.

The company, however, said it expects stimulus funding to have a positive impact on fourth-quarter and 2010 results.

Meanwhile, the consensus forecast for the company's full-year earnings has moved down a penny over the past month to 89 cents per share.

ILMN, a Zacks #3 Rank ("Hold") stock, is trading on extraordinarily high volume of approximately 9.4 million, compared to the average daily volume of about 1.4 million.

Email	Print	Share	RSS	Rate Pos	Rate Neg	Comment